Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results

Tisagenlecleucel demonstrated high response rates and a manageable safety profile in adults with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. However, lack of response and chimeric antigen receptor (CAR) T-cell exhaustion were observed in patients with programme...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaeger, Ulrich, Worel, Nina, McGuirk, Joseph P., Riedell, Peter A., Fleury, Isabelle, Du, Yan, Han, Xia, Pearson, David, Redondo, Santiago, Waller, Edmund K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225880/
https://www.ncbi.nlm.nih.gov/pubmed/36044388
http://dx.doi.org/10.1182/bloodadvances.2022007779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225880/
https://www.ncbi.nlm.nih.gov/pubmed/36044388
http://dx.doi.org/10.1182/bloodadvances.2022007779

Ejemplares similares